Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: A case report

Acta Dermato-Venereologica

Volumn 93, Issue 3, 2013, Pages 368-369

  Dahl, Christine ^a   Johansen, Claus ^a   Kragballe, Knud ^a   Braae Olesen, Anne ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; PROTEIN P40; THALIDOMIDE; USTEKINUMAB;

AGED; ALOPECIA; CASE REPORT; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAR FORMATION; SKIN ATROPHY; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; TELANGIECTASIA; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877001160     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1467     Document Type: Letter

References (10)

1. Jessop S, whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database syst rev 2009; CD002954.
2. Leonardi CL, kimball AB, Papp kA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (pHoENIX 1). Lancet 2008; 371: 1665-1674.
3. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses. J Der-matolog Treat 2008; 19: 318-326.
4. Johansen C, Vinter H, soegaard-madsen L, olsen LR, steiniche T, Iversen L, et al. preferential inhibition of the mrNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br J Dermatol 2010; 163: 1194-1204.
5. Bein D, kuehn E, Meuth AM, Amler S, Haust M, Nyberg F, et al. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLAsI. J Eur Acad Dermatol Venereol 2011; 25: 652-659.
6. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharza-deh S, et al. The CLAsI (Cutaneous Lupus Erythematosus Disease Area and severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-894.
7. Wong CK, Ho CY, Li EK, Lam CWK. Elevation of proin-fammatory cytokine (IL-18, IL-17, IL-12) and Th2 cyto-kine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-593.
8. Lauwerys BR, Van SJ, Houssiau FA. serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 2002; 11: 384-387.
9. De souza A, Ali-shaw T, strober BE, Franks AG. successful treatment of subacute lupus erythematosus with ustekinu-mab. Arch Dermatol 2011; 147: 896-898.
10. Winchester D, Duffn KC, Hansen C. Response to ustekinu-mab in a patient with both severe psoriasis and hypertropic cutaneus lupus. Lupus 2012; 21: 1007-1010.